Senator Tillis Says U.S. Needs CHIPS Act for Generic Drugs in Short Supply
In Senate hearing: imported generic drugs facing consistent drug shortages need a government incentive program to help labs make life-saving commodity drugs domestically.
In Senate hearing: imported generic drugs facing consistent drug shortages need a government incentive program to help labs make life-saving commodity drugs domestically.
The October trade deficit rose, but the biggest takeaway from the latest data is how much the China goods gap is in decline this year.
A recent study suggests that Americans prefer locally produced medications if they are unclear where the product was made or if the lab has received bad reviews from an FDA inspection.
The December Currency Misalignment Monitor found dollar overvaluation edging up once again, to 17.4% against the basket of 33 other currencies included in our model.
It should be a no-brainer to make sure that America’s investors don’t fund any of China’s military ambitions. And yet our very own Congressman, Patrick McHenry of North Carolina, is inexplicably blocking bipartisan congressional efforts to limit U.S. investments in China.
Big Tech is “big mad” with Biden administration pulling out of WTO digital trade initiative. Why it was a good idea to do so.
Why does anyone take China’s promises seriously? Following this week’s APEC conference, the U.S. is awash in headlines about the latest agreements between Biden and Xi, most of them not even in writing.
Another Indian lab recalling eye drops following recalls in October and instances of blindness caused by other imports from India in March.
China engagement not going too well. Supply chain risks spread to Vietnam, elsewhere, U.S. China Economic and Security Review Commission says in its annual report to Congress.
Customs and Border Protection are struggling to inspect nearly a billion small parcels bombarding the U.S. by international mail. Are they really up to this impossible task?